Peter Mac announced as a Partner of Choice with Amgen to accelerate cancer treatment discoveries
18 October 2023
Peter Mac will work alongside some of the world’s leading research centres as part of the ‘Amgen Partner of Choice’ network.
Amgen is one of the world’s leading biotechnology companies and the network aims to advance collaboration across industry and academia to accelerate treatment development for cancer patients.
Professor Jayesh Desai, Associate Director of Clinical Research at Peter Mac, said that it really spoke to the calibre and depth of research at Peter Mac to be the only Australian partner in the network.
“Amgen has chosen to partner with world-class clinical leaders at eight research centres around the world, and Peter Mac is proud to be one of those centres,” he said.
“The partnership will enable us to collaborate further with other academic centres to advance new treatment options for our patients.”
The network will create multiple collaboration channels globally with the goal of expediting the transition of new, transformational programs to leaders in the clinic.
Current Amgen Partners of Choice projects are focused on select disease areas and tumour types including thoracic, gastrointestinal and genitourinary cancers.